The rapid‐fire clinical successes from blocking the ligands of B7 superfamily, such as CTLA‐4 and PD‐1, have opened prospects for extending this potential cancer immunotherapy by inhibiting more recently discovered checkpoint ligands and receptors 26, 27, 28. This evidence concerns the gene CTLA4 and cancer.